Filtered By:
Drug: Rituxan
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 5018 results found since Jan 2013.
Clinical improvement in early onset interstitial lung disease using rituximab in children with anti-MDA5 positive juvenile dermatomyositis
CONCLUSION: This is the first study to examine the use of RTX in children with JDM and anti-MDA5 antibodies, with notable improvements ILD, cutaneous and musculoskeletal manifestations. Further studies are needed to better understand the efficacy of RTX on JDM disease related complications.PMID:37714547 | DOI:10.3899/jrheum.2023-0544
Source: J Rheumatol - September 15, 2023 Category: Rheumatology Authors: Malki Peskin Marilyn Mostowy Jennifer Velez Megan Perron Jessica Kurian Dawn M Wahezi Source Type: research
Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD)
BMJ Open Respir Res. 2023 Sep;10(1):e001580. doi: 10.1136/bmjresp-2022-001580.ABSTRACTINTRODUCTION: Progressive pulmonary fibrosis (PPF) includes any diagnosis of progressive fibrotic interstitial lung disease (ILD) other than idiopathic pulmonary fibrosis (IPF). However, disease progression appears comparable between PPF and IPF, suggesting a similar underlying pathology relating to pulmonary fibrosis. Following positive results in a phase II study in IPF, this phase III study will investigate the efficacy and safety of BI 1015550 in patients with PPF (FIBRONEER-ILD).METHODS AND ANALYSIS: In this phase III, double-blind, ...
Source: Respiratory Care - September 14, 2023 Category: Respiratory Medicine Authors: Toby M Maher Shervin Assassi Arata Azuma Vincent Cottin Anna-Maria Hoffmann-Vold Michael Kreuter Justin M Oldham Luca Richeldi Claudia Valenzuela Marlies S Wijsenbeek Carl Coeck Christina Schlecker Florian Voss Daniel Wachtlin Fernando J Martinez Source Type: research
Bortezomib and Vorinostat Therapy as Maintenance Therapy Post Autologous Transplant for Non-Hodgkin's Lymphoma Using R-BEAM or BEAM Transplant Conditioning Regimen
CONCLUSIONS: BV can be given post-ASCT for NHL and produces excellent disease-free and overall survival rates.PMID:37708877 | DOI:10.1159/000533944
Source: Acta Haematologica - September 14, 2023 Category: Hematology Authors: Leona A Holmberg David G Maloney Laura Connelly-Smith Source Type: research
Presentation and outcome of pediatric lupus nephritis from a large single centre contemporary cohort in Eastern India
CONCLUSION: Our study on a contemporary cohort of childhood LN highlights the importance of achieving CR and its feasibility.PMID:37707867 | DOI:10.1177/09612033231202843
Source: Lupus - September 14, 2023 Category: Rheumatology Authors: Debopoma Biswas Deblina Dasgupta Priyankar Pal Rajiv Sinha Source Type: research
Bortezomib and Vorinostat Therapy as Maintenance Therapy Post Autologous Transplant for Non-Hodgkin's Lymphoma Using R-BEAM or BEAM Transplant Conditioning Regimen
CONCLUSIONS: BV can be given post-ASCT for NHL and produces excellent disease-free and overall survival rates.PMID:37708877 | DOI:10.1159/000533944
Source: Acta Haematologica - September 14, 2023 Category: Hematology Authors: Leona A Holmberg David G Maloney Laura Connelly-Smith Source Type: research
Presentation and outcome of pediatric lupus nephritis from a large single centre contemporary cohort in Eastern India
CONCLUSION: Our study on a contemporary cohort of childhood LN highlights the importance of achieving CR and its feasibility.PMID:37707867 | DOI:10.1177/09612033231202843
Source: Lupus - September 14, 2023 Category: Rheumatology Authors: Debopoma Biswas Deblina Dasgupta Priyankar Pal Rajiv Sinha Source Type: research
Bortezomib and Vorinostat Therapy as Maintenance Therapy Post Autologous Transplant for Non-Hodgkin's Lymphoma Using R-BEAM or BEAM Transplant Conditioning Regimen
CONCLUSIONS: BV can be given post-ASCT for NHL and produces excellent disease-free and overall survival rates.PMID:37708877 | DOI:10.1159/000533944
Source: Acta Haematologica - September 14, 2023 Category: Hematology Authors: Leona A Holmberg David G Maloney Laura Connelly-Smith Source Type: research
Prognostic Markers in the Era of Targeted Therapies
Acta Haematol. 2023 Sep 13. doi: 10.1159/000533704. Online ahead of print.ABSTRACTBackground Small molecules targeting Bruton's tyrosine kinase (BTK) and B-cell lymphoma-2 have become the standard of care for the treatment of chronic lymphocytic leukemia (CLL), replacing chemoimmunotherapy (CIT) in most clinical settings. Ongoing trials explore targeted combinations and minimal residual disease-driven treatment cessation. These dramatic shifts in the current and upcoming treatment landscape of CLL raise the need to reevaluate existing prognostic markers and develop novel ones. Summary This review examines prognostic marker...
Source: Acta Haematologica - September 13, 2023 Category: Hematology Authors: Sorang Kang Inhye E Ahn Source Type: research
Cost of Disease Progression in Diffuse Large B-Cell Lymphoma After Frontline Treatment With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
CONCLUSION: Treated progression of DLBCL increases adjusted PPPM costs by over $8000 compared with no progression.PMID:37704514 | DOI:10.1016/j.clml.2023.08.005
Source: Clinical Lymphoma and Myeloma - September 13, 2023 Category: Cancer & Oncology Authors: John M Burke Anthony Masaquel Rongrong Wang Farah Hossain Jia Li Summera Qiheng Zhou Carmen D Ng Matthew Matasar Source Type: research
